Ivor Benjamin MD

Obstetrics & Gynecology•Phoenix, AZ

Gynecologic Oncology

Arizona Center for Cancer Care

Join to View Full Profile

500 W Thomas RdSte 600Phoenix, AZ 85013
Phone+1 602-406-6000
Fax+1 602-406-7424

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Gynecologic Oncology, 1991 - 1994
University of Pennsylvania Health SystemResidency, Obstetrics and Gynecology, 1987 - 1991
Columbia University Vagelos College of Physicians and SurgeonsClass of 1987

Certifications & Licensure

AZ State Medical License 2008 - 2025
NM State Medical License 2011 - 2011
PA State Medical License 1988 - 2002
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Clinical Trials

Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 3
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Start of enrollment: 2009 Mar 23
Active, not recruiting
Phase 3
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Start of enrollment: 2009 Jun 29
Active, not recruiting
Phase 3
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2009 Aug 17
Active, not recruiting
Phase 3
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Start of enrollment: 2009 Sep 14
ACTIVE_NOT_RECRUITING
PHASE2
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
ACTIVE_NOT_RECRUITING
PHASE3
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Start of enrollment: 2009 Nov 01
Terminated
Phase 3
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Start of enrollment: 2010 Oct 12
ACTIVE_NOT_RECRUITING
PHASE3
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Start of enrollment: 2010 Apr 12
Active, not recruiting
Phase 3
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Start of enrollment: 2010 Aug 01
Completed
Phase 2
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer Start of enrollment: 2011 Apr 04
Completed
Phase 2
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Start of enrollment: 2011 Aug 15
Active, not recruiting
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Start of enrollment: 2012 Jan 09
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

40 citations
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label...
Stephanie Gaillard, Ana Oaknin, Isabelle Ray-Coquard, Ignace Vergote, Giovanni Scambia
Gynecologic Oncology. 2021-11-01
32 citations
Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer
Bradley J. Monk, Heather J. Dalton, John H. Farley, Dana M. Chase, Ivor Benjamin
Critical Reviews in Oncology/hematology. 2013-05-01
17 citations
Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer
Bradley J. Monk, Heather J. Dalton, Ivor Benjamin, Adnan Tanovic
Current Pharmaceutical Design. 2012-07-31

Ivor Benjamin MD

Dr. Benjamin is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Viewing the full profile is available to verified healthcare professionals only.